The MAVERICK Trial for Small-Cell Lung Cancer

Clinical Trial Title

S1827: MRI brain surveillance alone versus MRI surveillance and prophylactic cranial irradiation (PCI): A randomized phase III trial in small-cell lung cancer (MAVERICK).

National Clinical Trial Number:

NCT04155034

Clinical Trial Protocol Description:

This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in treating patients with small cell lung cancer. MRI scans are used to monitor the possible spread of the cancer with an MRI machine over time. PCI is radiation therapy that is delivered to the brain in hopes of preventing spread of cancer into the brain. The use of brain MRI alone may reduce side effects of receiving PCI and prolong patients' lifespan. Monitoring with MRI scans alone (delaying radiation until the actual spread of the cancer) may be at least as good as the combination of PCI with MRI scans.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Have a histologically confirmed diagnosis of small-cell lung cancer (SCLC).
  • Have no evidence or history of brain metastases or leptomeningeal disease.
  • Have not received prior radiotherapy to the brain or whole brain therapy.
  • Have had a response to first-line therapy and no evidence of progression.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Study Details

Clinical Trial Investigator

Gaurav Marwaha, MD

Contact Information

Rush Cancer Center Clinical Trials Office